Further, FTO levels were significantly elevated in nilotinib-treated AML patients and in CML patients non-responding to imatinib or nilotinib therapy (Fig. S7B). This evidence concerns the gene FTO and chronic myelogenous leukemia, BCR-ABL1 positive.